Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
NCT ID NCT07700446
First seen Jul 14, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether a temporary higher dose of upadacitinib (45 mg daily) can bring ulcerative colitis back under control in adults whose disease flared up while on the standard 30 mg maintenance dose. Participants receive the higher dose for 8 to 16 weeks, then may step down to the maintenance dose if their symptoms and colon inflammation improve. The goal is to see if this re-induction approach can recapture clinical response without needing to switch to a different medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- upadacitinib (Rinvoq), a JAK1 inhibitor, given as a 45 mg daily re-induction dose
- What this could lead to
- If successful, this re-induction strategy could offer a way to regain disease control for ulcerative colitis patients without switching to a different drug.
- What could go wrong
- This is a single-arm, open-label study with no placebo group, so results may be less definitive. Higher doses of upadacitinib carry increased risks of infection and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stool test may predict gut healing in ulcerative colitis
- New staining technique could sharpen healing assessment in IBD
- Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults
- Study aims to keep workers with chronic illnesses on the job
- Real-World study tests Mirikizumab's power against ulcerative colitis
- New oral drug INT-210 aims to tame ulcerative colitis Flare-Ups